Since the SARS epidemic in 2003, coronaviruses have been on the watch list for emerging pathogens, and the ongoing outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) confirmed that they represent a serious threat. No specific drugs exist against coronaviruses so far, but an article published on May 29th in PLOS Pathogens introduces a new inhibitor of coronaviruses and implicates a specific process in the life cycle of these viruses that it blocks.
Searching for inhibitors of coronaviruses, an international team of scientists led by Edward Trybala, from the University of Gothenburg, Sweden, and Volker Thiel, from the University of Berne, Switzerland, identified a compound called K22. They initially discovered that K22 had antiviral activity against a relatively harmless coronavirus that causes mild cold-like symptoms in humans. Follow-up experiments showed that the compound was effective against all other coronaviruses tested, including the SARS and MERS coronaviruses. The researchers also demonstrated efficient inhibition of virus in cells that line the human airways and are the natural port of entry for respiratory viruses.
Examining K22’s mechanism of action, they discovered that the compound acts at an early step during the production of coronavirus in human host cells. Human cells are subdivided into different “compartments”, for example the nucleus that contains the genetic information, or the mitochondria, which are the cell’s power plants. Each compartment is surrounded by a wall-like structure called a “membrane”. In order to multiply (i.e. manufacture new virus) and spread the infection, coronaviruses need to usurp and re-shape some of the membranes in the human host cells to build a sort of scaffolding for their virus production machinery. The results here show that K22 inhibits coronaviruses by preventing this use of host membranes for viral production.
“The remarkable efficacy of K22-mediated inhibition of coronavirus replication”, the authors say, “confirms that the employment of host cell membranes for viral RNA synthesis is a crucial step in the coronavirus life cycle, and importantly, demonstrates that this step is extremely vulnerable and also druggable for antiviral intervention” Because the identification of K22 and its proposed mode-of-action is only the first, preclinical, step towards a therapeutic use, they also argue that “one important lesson of the past SARS and recent MERS coronavirus outbreaks is the need to invest significant efforts to developing efficacious and approved drugs to increase preparedness and combat coronavirus infections”.
Lundin A, Dijkman R, Bergstro¨m T, Kann N, Adamiak B, et al. (2014) Targeting Membrane-Bound Viral RNA Synthesis Reveals Potent Inhibition of Diverse Coronaviruses Including the Middle East Respiratory Syndrome Virus. PLoS Pathog 10(5): e1004166. doi:10.1371/journal.ppat.1004166, http://dx.plos.org/10.1371/journal.ppat.1004166
Edward Trybala, e-mail: firstname.lastname@example.org
Volker Thiel, e-mail: email@example.com
Authors and Affiliations:
Anna Lundin, University of Gothenburg, Göteborg, Sweden
Ronald Dijkman, Kantonal Hospital St.Gallen, St.Gallen, Switzerland; Institute of Virology and Immunology, Berne and Mittelhaüsern, Switzerland
Tomas Bergström, University of Gothenburg, Göteborg, Sweden
Nina Kann, Chalmers University of Technology, Göteborg, Sweden
Beata Adamiak, University of Gothenburg, Göteborg, Sweden
Charles Hannoun, University of Gothenburg, Göteborg, Sweden
Eveline Kindler, Kantonal Hospital St.Gallen, St.Gallen, Switzerland; Institute of Virology and Immunology, Berne and Mittelhaüsern, Switzerland
Hulda R. Jónsdóttir, Kantonal Hospital St.Gallen, St.Gallen, Switzerland; Institute of Virology and Immunology, Berne and Mittelhaüsern, Switzerland
Doreen Muth, University of Bonn Medical Centre, Bonn, Germany
Joeri Kint, Wageningen University, The Netherlands; Bioprocess Technology & Support, The Netherlands
Maria Forlenza, Wageningen University, The Netherlands,
Marcel A. Müller, University of Bonn Medical Centre, Germany
Christian Drosten, University of Bonn Medical Centre, Germany
Volker Thiel, Kantonal Hospital St.Gallen, St.Gallen, Switzerland; Institute of Virology and Immunology, Berne and Mittelhaüsern, Switzerland; University of Berne, Switzerland
Edward Trybala, University of Gothenburg, Göteborg, Sweden
This work was supported by the Swiss National Science Foundation (VT, RD, EK), the 3R Research Foundation, Switzerland (VT, RD, HRJ), the German Research Foundation (Priority Programme 1596, VT), Swedish grants 71650 and 71690 from the Sahlgrenska University Hospital Läkarutbildningsavtal/ALF, and grant from Mizutani Foundation. AL was supported by grant MN58/07 from the Torsten and Ragnar Söderberg Foundation. CD was supported by the European Union FP7 projects EMPERIE (contract number 223498) and ANTIGONE (contract number 278976), the German Research Foundation (DFG grant DR 772/3-1), as well as the German Ministry of Education and Research (BMBF SARS II, 01KI1005A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
JK is employed by a commercial company, Merck Animal Health. This does not alter our adherence to all PLOS Pathogens policies on sharing data and materials.